#25. Muneer A. Satter Buys $15M of Akebia Therapeutics, Inc. latest buy: 07/05/2017
During the last six months, Satter bet big on AKBA:
Muneer A. Satter
Akebia Therapeutics is a biopharmaceutical company focused on developing and delivering therapeutics for patients based on hypoxia-inducible factor (HIF), biology. Co.'s primary product candidate, vadadustat, a HIF-prolyl hydroxylases inhibition, is in Phase 3 development for the treatment of anemia associated with chronic kidney disease (CKD). The vadadustat Phase 3 program in non-dialysis dependent-CKD patients with anemia, called PRO2TECT, and in dialysis dependent-CKD patients with anemia, called INNO2VATE, is designed to evaluate patients with once daily oral dosing of vadadustat against recombinant erythropoiesis-stimulating agents, active comparator, darbepoetin alfa.
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.